USD 0.0
(0.0%)
Year | Operating Income | Operating Income Growth |
---|---|---|
2021 | -39.73 Million USD | 15.78% |
2020 | -47.17 Million USD | 0.0% |
Year | Operating Income | Operating Income Growth |
---|---|---|
2022 Q2 | -10.65 Million USD | 21.38% |
2022 Q1 | -13.54 Million USD | 0.0% |
2021 FY | -39.73 Million USD | 15.78% |
2021 Q2 | -13.23 Million USD | 0.0% |
2020 FY | -47.17 Million USD | 0.0% |
Name | Operating Income | Operating Income Difference |
---|---|---|
AstraZeneca PLC | 8.19 Billion USD | 100.485% |
Bristol-Myers Squibb Company PFD CONV 2 | 17.24 Billion USD | 100.23% |
CSPC Pharmaceutical Group Limited | 7.01 Billion USD | 100.566% |
Novartis AG | 9.76 Billion USD | 100.407% |
PT Kalbe Farma Tbk. | 3625.13 Billion USD | 100.001% |